The Passage Bio team is aware of the recent announcement regarding the discontinuation of a gene therapy clinical study in FTD caused by GRN mutations. We recognize that this news may be disappointing for individuals and families who were following that research orconsidering participation.

We want to share, with care and respect for this moment, that research in FTD-GRN continues, and that options for clinical research participation still exist for individuals who may wish to explore them now or in the future.

Passage Bio continues to support ongoing research efforts in FTD-GRN. Individuals and families interested in learning more about current clinical research opportunities are encouraged to visit trusted community resources, such as CureGRN and AFTD, which provide up-to-date information on clinical trials and research studies across the FTD community.

We believe it is crucial that families have access to clear information and the time and space to decide what is right for them.

Our commitment remains to the FTD community — to listen, to learn, and to support patients and caregivers in ways that honor their experience and priorities.

With care,
Passage Bio